SCHEMBL1000271

SCHEMBL1000271

CCOC(=O)CSc1sc(NC(=O)N(C2CCCCC2)C2CCCCC2)nc1C

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.40
KDM4E B2RXH2 3/20 0.40
NPC1 O15118 2/20 0.40
MEN1 O00255 2/20 0.40
KMT2A Q03164 2/20 0.40
HSD17B10 Q99714 2/20 0.39
GAA P10253 1/20 0.39
CCNB2 O95067 1/20 0.39
CCNE2 O96020 1/20 0.39
CDK1 P06493 1/20 0.39
CDK4 P11802 1/20 0.39
CCNB1 P14635 1/20 0.39
CCND1 P24385 1/20 0.39
CCNE1 P24864 1/20 0.39
CDK2 P24941 1/20 0.39
CCNB3 Q8WWL7 1/20 0.39
HPGD P15428 3/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
RAB9A P51151 1/20 0.39
LMNA P02545 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1002401 0.90 ALDH1A1 (0.39) ALDH1A1KDM4ENPC1MEN1KMT2A
SCHEMBL999663 0.87 SMN1; SMN2 (0.41) ALDH1A1KDM4ENPC1SMN1; SMN2RAB9A
SCHEMBL999362 0.82 KMT2A (0.60) ALDH1A1KDM4ENPC1MEN1KMT2A
SCHEMBL1001791 0.82 KMT2A (0.60) ALDH1A1KDM4ENPC1MEN1KMT2A
SCHEMBL998784 0.81 KMT2A (0.59) ALDH1A1KDM4ENPC1MEN1KMT2A
SCHEMBL1000661 0.81 NPC1 (0.40) ALDH1A1KDM4ENPC1SMN1; SMN2RAB9A
SCHEMBL999060 0.81 NPC1 (0.40) ALDH1A1KDM4ENPC1SMN1; SMN2RAB9A
SCHEMBL999629 0.80 CCNE1 (0.64) ALDH1A1KDM4ENPC1MEN1KMT2A
SCHEMBL999973 0.80 CCNE1 (0.64) ALDH1A1KDM4ENPC1MEN1KMT2A
SCHEMBL998855 0.80 CCNE1 (0.64) ALDH1A1KDM4ENPC1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2444397-A1 Heteroaryl-ureas and their use as glucokinase activators Novo Nordisk A/S (DK) 2012-04-25 EP disclosed
US-20110060019-A1 HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS NOVO NORDISK A/S (DK) 2011-03-10 US disclosed
US-7872139-B2 e.g.1,1-Dicyclohexyl-3-[5-(pyridin-2-ylsulfanyl)-thiazol-2-yl]-urea; useful for the management, treatment, control, or adjunct treatment of diseases, where increasing glucokinase activity is beneficial, in particular, type 2 diabetes NOVO NORDISK A/S (DK) 2011-01-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110060019-A1 HETEROARYL-UREAS AND THEIR USE AS GLUCOKINASE ACTIVATORS GCK, HK1, HK2 ALDH1A1 1548/4885KDM4E 2328/4885NPC1 1530/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.